MARATTO

article · International Journal of Molecular Sciences

Kaiso Is a Novel TAZ-Interaction Partner That Promotes Hepatic Stellate Cell Activation and Regulates the Downstream lncRNA HIF1A-AS3

2026Open accessAin Shams University

Abstract

Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of hepatic stellate cell (HSC) activation and liver fibrosis. While the canonical YAP/TAZ-TEAD axis is well-characterized, non-canonical interaction partners and downstream long non-coding RNAs (lncRNAs) that orchestrate fibrogenic programs in HSCs remain undefined. Using BioID and next-generation sequencing (NGS) in LX-2 cells, we identified YAP/TAZ-interactomes and YAP/TAZ-regulated lncRNAs. BioID results and proximity ligation assay (PLA) identified the transcription factor Kaiso as a TAZ interaction partner. Functionally, Kaiso knockdown suppressed key aspects of HSC activation in LX-2 cells. We next integrated our NGS results from YAP/TAZ-knockdown in LX-2 cells with publicly available Kaiso ChIP-seq data. This identified HIF1A-AS3 as a common downstream lncRNA. ChIP-qPCR confirmed direct binding of Kaiso to the HIF1A-AS3 promoter. Furthermore, HIF1A-AS3 silencing mirrored the functional effects of Kaiso knockdown. Global proteomic profiling following knockdown of TAZ, Kaiso, or HIF1A-AS3 revealed a network of commonly regulated proteins enriched for pathways central to HSC activation. In conclusion, we establish Kaiso as a novel TAZ interaction partner and identify HIF1A-AS3 as a shared downstream target of TAZ and Kaiso, suggesting a potential profibrotic regulatory network that promotes HSC activation and may represent a therapeutic target for liver fibrosis.

Research topics

  • Hippo pathway signaling and YAP/TAZ
  • Liver physiology and pathology
  • Proteoglycans and glycosaminoglycans research

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3390/ijms27177847

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.